Clinical Trials Directory

Trials / Conditions / Relapsed Ovarian Cancer

Relapsed Ovarian Cancer

11 registered clinical trials studyying Relapsed Ovarian Cancer — 4 currently recruiting.

StatusTrialSponsorPhase
Not Yet RecruitingFluzoparib Combined With Apatinib in Relapsed Ovarian Carcinoma Maintenance Treatment
NCT06081595
Jin LiPhase 2
RecruitingAdaptive ChemoTherapy for Ovarian Cancer in Patients With Replased Platinum-sensitive High Grade Serous or Hig
NCT05080556
University College, LondonPhase 2
Not Yet RecruitingFluzoparib and Apatinib Versus Fluzoparib in Relapsed Ovarian Carcinoma Maintenance Treatment
NCT05479487
Xiaohua Wu MDPhase 2
Active Not RecruitingOSE2101 Alone or in Combination With Pembrolizumab vs BSC in Patient With Platinum-sensitive Recurrent OC
NCT04713514
ARCAGY/ GINECO GROUPPhase 2
TerminatedA Study of AK112 Combined With PARP Inhibitor in the Treatment of Recurrent Ovarian Cancer
NCT04999605
AkesoPhase 1 / Phase 2
RecruitingSecondary Cytoreduction Followed by Chemotherapy Versus Chemotherapy Alone in Relapsed Ovarian Cancer After PA
NCT05607329
Women's Hospital School Of Medicine Zhejiang UniversityN/A
CompletedA Phase 2 Trial of Fluzoparib Combined With Apatinib Versus Fluzoparib Monotherapy in Treatment With Relapsed
NCT04517357
Jiangsu HengRui Medicine Co., Ltd.Phase 2
UnknownReprab Study: PLD + Trabectedin Rechallenge
NCT04887961
Fondazione Policlinico Universitario Agostino Gemelli IRCCSPhase 2
CompletedOlaparib Tablets Maintenance Monotherapy Ovarian Cancer Patients After Complete or Partial Response to Platinu
NCT03534453
AstraZenecaPhase 3
CompletedNon-interventional European Study of Trabectedin + PLD in the Treatment of Relapsed Ovarian Cancer (ROC) Patie
NCT02825420
PharmaMar—
Active Not RecruitingOlaparib Treatment in BRCA Mutated Ovarian Cancer Patients After Complete or Partial Response to Platinum Chem
NCT01874353
AstraZenecaPhase 3